Skip to main content
Curocell Inc. logo

Curocell Inc. — Investor Relations & Filings

Ticker · 372320 ISIN · KR7372320002 KO Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2026-05-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 372320

About Curocell Inc.

https://curocellbtx.com/

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 87% confidence The document is a regulatory notification to the Korean Financial Services Commission/Korea Exchange regarding the grant of stock options (“주식매수선택권 부여”). It details the number of options, exercise price, vesting conditions, and the corporate resolution basis. This constitutes an announcement of a capital change through the issuance of new shares upon exercise of options. It is not a full financial report, earnings release, management change, or meeting materials, but rather a specific share issue notification. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-27 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청)
Regulatory Filings Classification · 90% confidence The document is a Korean stock exchange (KRX) disclosure of a material business event: the company has applied for approval to change its clinical trial plan. It does not present financial statements or data, nor is it a formal annual or interim report, audit, earnings release, or any of the specified specialized filings (e.g., M&A, director dealings, dividends). It is a general regulatory announcement about an important corporate development. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 85% confidence The document is a Korean regulatory filing titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” which reports an officer’s (executive’s) personal shareholdings and a change (sale) of common stock on specific dates. This matches an insider transaction report by a director or executive. Therefore, it falls under Director’s Dealing (Code: DIRS).
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (quarterly report) covering the period 2026-01-01 to 2026-03-31 and contains comprehensive financial and operational disclosures (company overview, governance, capital changes, business activities, pipeline details). It is filed with the Korean Financial Services Commission/KRX as a standard quarterly (interim) report under K-IFRS. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(약식)' which translates to 'Report on Large Shareholding Status (Abbreviated)'. It contains detailed information about shareholdings, changes in share ownership, and related parties. The document references specific dates and shareholding percentages, and it is a regulatory filing related to disclosure of large shareholdings under capital market laws. There is no indication that this is an annual report, earnings release, or management report. It is not a proxy solicitation or voting result announcement. The content fits the definition of a Major Shareholding Notification, which involves notification of changes in significant share ownership levels. The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2026-05-07 Korean
투자판단관련주요경영사항 (림카토주(안발셀) 식품의약품안전처 품목허가 승인)
Regulatory Filings Classification · 85% confidence The document is a Korean stock exchange disclosure titled “투자판단 관련 주요경영사항” announcing MFDS approval of a pharmaceutical product. It is a regulatory announcement of a corporate event, not a financial report, earnings release, or other specific filing type. It falls under general regulatory filings (fallback category).
2026-04-29 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.